Company profile

MedImmune LLC

Privately held: no public share price

Assets

(6 total)
6Total Assets
3Approved
3Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 6 of 6 assets
Target & Modality
Anifrolumab
Approved
Type I interferon receptor · Type I interferon receptor subunit 1 (IFNAR1)Monoclonal antibody
Systemic Lupus Erythematosus
Benralizumab(Fasenra)
Approved
IL-5 receptor alpha · IL-5 receptor alpha (IL-5Rα / CD125); Fc region additionally engages · IL-5 receptor alpha (IL5RA) on eosinophils/basophilsMonoclonal antibody
Asthma
Omalizumab(Xolair)
Approved
Undisclosed / early pipeline · IgEMonoclonal antibody
Asthma
Monalizumab
Phase 3
NKG2AMonoclonal antibody
Non-Small Cell Lung Cancer
Oleclumab
Phase 3
CD73Monoclonal antibody
Non-Small Cell Lung Cancer
Tremelimumab
Phase 3
CTLA-4Monoclonal antibody
Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.